Table 3 Treatments and procedures according to gender, stratified in age intervals.
| ⩽59 years | 60–69 years | 70–79 years | ⩾80 years | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M (n = 7893) | W (n = 2621) | p Value | M (n = 8326) | W (n = 3654) | p Value | M (n = 11 216) | W (n = 6939) | p Value | M (n = 6585) | W (n = 6547) | p Value | |
| Acute treatment | ||||||||||||
| Heparin/LMWH | 64 | 64 | 0.70 | 63 | 63 | 0.67 | 58 | 58 | 0.94 | 49 | 48 | 0.27 |
| Nitroglycerin iv | 31 | 32 | 0.28 | 33 | 33 | 0.60 | 32 | 33 | 0.21 | 32 | 30 | 0.10 |
| GPIIb/IIIa inhibitor | 9 | 8 | 0.07 | 7 | 6 | 0.006 | 5 | 4 | 0.18 | 3 | 2 | 0.02 |
| Procedures* | ||||||||||||
| Stress test | 36 | 35 | 0.18 | 35 | 31 | <0.001 | 27 | 22 | <0.001 | 9 | 4 | <0.001 |
| Echocardiography | 47 | 43 | <0.001 | 46 | 45 | 0.28 | 45 | 45 | 0.53 | 35 | 31 | <0.001 |
| Coronary angiography | 54 | 53 | 0.37 | 46 | 45 | 0.17 | 32 | 30 | 0.003 | 10 | 8 | <0.001 |
| PCI | 30 | 26 | <0.001 | 22 | 22 | 0.96 | 13 | 14 | 0.25 | 4 | 4 | 0.26 |
| CABG | 7 | 6 | <0.001 | 9 | 7 | <0.001 | 7 | 6 | <0.001 | 2 | 1 | <0.001 |
| Medication at discharge | ||||||||||||
| ACE inhibitor | 30 | 25 | <0.001 | 37 | 34 | 0.002 | 41 | 40 | 0.10 | 37 | 37 | 0.65 |
| Aspirin/other thrombocyte inhibitor | 93 | 93 | 0.13 | 90 | 91 | 0.19 | 86 | 85 | 0.31 | 81 | 80 | 0.05 |
| β‐blocker | 89 | 86 | <0.001 | 86 | 85 | 0.06 | 80 | 80 | 0.66 | 70 | 70 | 0.82 |
| Lipid‐lowering drugs | 71 | 63 | <0.001 | 64 | 66 | 0.03 | 46 | 49 | <0.001 | 19 | 19 | 0.27 |
Data are given as percentages unless otherwise indicated.
CABG, coronary artery bypass grafting; GPIIb/IIIa, glycoprotein IIb/IIIa; LMWH, low molecular weight heparin; M, men; PCI, percutaneous coronary intervention; W, women.
*Performed during hospital stay.